Hepatitis C News and Research

Latest Hepatitis C News and Research

Dead human tissue illegally used in surgery

London Health Sciences Centre is investigating if its surgeons used human tissue products that were recalled because they might have been taken illegally from corpses at funeral homes in the United States.

31 Oct 2005

Morphine withdrawal enhances hepatitis C virus (HCV) replicon expression

Researchers at the University of Pennsylvania have demonstrated that morphine withdrawal complicates hepatitis C by suppressing IFN-alpha-mediated immunity and enhancing virus replication.

30 Oct 2005

Hepatitis C linked to illegal blood donation in China

Research in a rural province of central China has documented that illegal blood donation practices led to high hepatitis C virus (HCV) infection rates in blood and plasma donors during the 1980s and early 1990s, and that failure to screen for HCV in transfusion recipients increased their risk of infection as well

20 Oct 2005

Evidence is mounting to link toxoplasmosis with schizophrenia

Keep pet cats inside, stop feeding strays, cook meat sufficiently and reconsider the way the veterinary profession and public health agencies think - and teach - about the zoonotic pathogen Toxoplasma gondii.

18 Oct 2005

Drug company warns of risk of liver problems with antidepressant

The warning about possible liver-related problems with the depression drug, Cymbalta, has been expanded and doctors are being cautioned against its use in chronic liver disease patients.

18 Oct 2005

Harvard study finds vaccines boost economies of poor countries

Immunization programs in impoverished countries not only save lives, they boost economies, finds a study by researchers with the Harvard School of Public Health (HSPH) published in the current edition of World Economics.

16 Oct 2005

Liver services in the United Kingdom need better funding and better staffing

Mortality from liver disease is increasing in the UK. In 2000 liver disease killed more men than Parkinson's disease and more women than cancer of the cervix. Deaths from alcoholic liver disease has doubled in the past 10 years, while liver disease arising from hepatitis C infection is expected to treble by 2020.

13 Oct 2005

Infants and adolescents vaccinated against hepatitis B are protected for over 10 years after immunisation

...concludes a study in this week’s issue of The Lancet. The authors state that booster doses of vaccine do not seem necessary to ensure long-term protection.

13 Oct 2005

Whooping cough vaccine 90 percent effective

A vaccine to protect adults and adolescents against illness due to Bordetella pertussis infection--or whooping cough--has proved more than 90 percent effective in a national, large-scale clinical study, according to research results published in this week's issue of The New England Journal of Medicine.

12 Oct 2005

New hormone discovery has implications for liver diseases

Researchers at UT Southwestern Medical Center have discovered that the small intestine communicates with the liver to control the production of bile acids - a finding that has great medical implications in treating people at risk for certain types of liver disease.

11 Oct 2005

Third Wave Technologies files patent suits against Chiron and Bayer

The company last Friday filed suit against Digene Corp., seeking a court ruling supporting Third Wave's right to sell its human papilloma virus (HPV) products. Third Wave today also filed suit against Chiron Corp., Bayer Corp., and Bayer HealthCare LLC asking for a similar ruling about its right to sell its hepatitis C virus products.

11 Oct 2005

20 percent of people with chronic hepatitis C who receive a liver transplant will develop advanced cirrhosis

A new study from the University of North Carolina at Chapel Hill School of Medicine may have found a way to identify those at greatest risk, thereby allowing doctors to decide who should receive treatment that could save the transplanted organ. The new findings appear in the October issue of the journal Liver Transplantation.

9 Oct 2005

Potential biomarker that could be used to predict who might develop hepatic fibrosis

Two new studies on Hepatitis C (HCV) patients who underwent liver transplants examined a potential biomarker that could be used to predict who might develop hepatic fibrosis, a formation of scar-like tissue that can lead to cirrhosis.

3 Oct 2005

Greasing the gears that drive the interferon signal

Interferon -- a critical protein that mediates the body's defense against a wide variety of infectious agents and tumors -- may soon have greater therapeutic value as the result of a new study by researchers at Washington University School of Medicine in St. Louis.

3 Oct 2005

Pain-free needles!

Millions of fearful patients could be saved the pain of vaccinations thanks to revolutionary pain-free needles to be revealed today for the first time at the British Pharmaceutical Conference in Manchester.

28 Sep 2005

Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in children

The Nonalcoholic Steatohepatitis (NASH) Clinical Research Network has launched its second clinical trial to study NASH, a liver disease that resembles alcoholic liver disease but occurs in patients who drink little or no alcohol. The first trial, launched in January of this year, focuses on adults, while the second trial studies the disease in children.

27 Sep 2005

Research highlights the role of viral sequence analysis in improving our overall understanding of hepatitis A cases in the U.S.

Novel use of genetic testing methods helped public health officials control and limit the further spread of four outbreaks of foodborne hepatitis A virus in 2003 related to the consumption of green onions, according to a detailed analysis published in the October 15 issue of The Journal of Infectious Diseases, now available online.

26 Sep 2005

Drug that blocks acid buildup inside cells revs up the immune response to vaccines

Reporting in the current issue of The Journal of Experimental Medicine, Vincenzo Barnaba and his team at the University of Rome show that people receiving booster shots against hepatitis B virus developed more robust immune responses if given a widely used anti-malaria drug called chloroquine.

21 Sep 2005

Stressgen granted new U.S. patent for treatment of Hepatitis B

Stressgen Biotechnologies announced today that the U.S. Patent and Trademark Office granted Patent Number 6,921,534 covering fusion protein compositions comprised of a hepatitis B virus (HBV) antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins, and methods of treating an HBV infection using these fusion proteins.

7 Sep 2005